-+ 0.00%
-+ 0.00%
-+ 0.00%

Stevanato Group Says Liraglutide-Based Combination Products Incorporating Its Proprietary Alina Pen Injector Platform Receives Marketing Authorizations In Europe

Benzinga·07/30/2026 10:38:32
Listen to the news

The regulatory approvals cover therapies for diabetes and weight management, further expanding the commercial adoption of Stevanato Group's proprietary Alina® pen injector platform across Europe.

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Marketing Authorization Holders.